Bioavailability evaluation on a new food component from soybeans

为了评价大豆主要抗癌药物鲍曼-伯克蛋白酶抑制剂（Bowman-birk protease inhibitor， BBI）的生物利用度，我们尝试建立一种新的酶联免疫吸附试验（ELISA）系统，该系统可以高灵敏度地选择性测定体内BBI水平。采用针对BBI的单克隆抗体和多克隆抗体，建立了一种新的检测BBI的ELISA系统。为提高系统的检测灵敏度，对系统中堵塞剂的测定等环节进行了修改。结果表明，与其他已建立的蛋白检测elisa系统相比，该系统具有相同或更高的检测灵敏度，表明该系统可以检测体内BBI水平。

In order to evaluate bioavailability of Bowman-birk protease inhibitor (BBI), a major anticancer agent involved in soybeans, we tried to establish a new ELISA system which can selectively BBI level in vivo with a high sensitivity. We established a new ELISA system for BBI detection, using monoclonal and polyclonal antibodies towards BBI. To improve detection sensitivity in the system, we changed several points in the system such as determination of blocking agent. As a result, the system had equal or higher detection sensitivity compared to other established protein detectionELISA systems, indicating that this system could detect BBI level in vivo.